Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Ginkgo Bioworks Holdings Q2 EPS $(1.10) Beats $(1.56) Estimate, Sales $50.00M Beat $41.61M Estimate

Author: Benzinga Newsdesk | August 07, 2025 04:11pm
Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(1.10) per share which beat the analyst consensus estimate of $(1.56) by 29.49 percent. This is a 75 percent increase over losses of $(4.40) per share from the same period last year. The company reported quarterly sales of $50.00 million which beat the analyst consensus estimate of $41.61 million by 20.16 percent. This is a 11.04 percent decrease over sales of $56.21 million the same period last year.

Posted In: DNA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist